Aetna Better Health® of Michigan

PROVIDER NOTICE

Participation in the CMS Cell & Gene Therapy (CGT) Access Model

Effective Date: January 1, 2026
Program End Date: December 31, 2036

Overview

Aetna Better Health® of Michigan (ABHMI) is partnering with the Michigan Department of Health and Human Services (MDHHS) as Michigan participates in the Centers for Medicare & Medicaid Services (CMS) Cell & Gene Therapy (CGT) Access Model.

This CMS Innovation Model expands Medicaid member access to transformative gene therapies while aligning drug payment with long-term clinical outcomes. The initial focus of the model is gene therapy for Sickle Cell Disease (SCD).

Additional CMS information is available at:
https://www.cms.gov/priorities/innovation/innovation-models/cgt

Gene Therapies Included

The following FDA-approved gene therapies for SCD are included in the CGT Access Model:

- **Casgevy®** (exagamglogene autotemcel)
- **Lyfgenia®** (lovotibeglogene autotemcel)

Coverage and Prior Authorization

- These gene therapies are carved out of Medicaid managed care and are covered through Medicaid Fee-for-Service (FFS).
- MDHHS processes all prior authorizations for ABHMI members.

- Coverage criteria and prior authorization requirements can be found at: **www.michigan.gov/MedicaidProviders**
  → CHAMPS
  → Prior Authorization
  → Cell & Gene Therapy Access Model
- Claims may be billed as professional or pharmacy claims, depending on provider configuration. Providers should ensure duplicate billing does not occur.

Authorized Michigan Treatment Centers

Casgevy®

- Henry Ford Hospital – Detroit
- University of Michigan Health – Ann Arbor
- Corewell Health – Helen DeVos Children's Hospital – Grand Rapids

Lyfgenia®

- Children's Hospital of Michigan – Detroit
- University of Michigan Health – Ann Arbor

Only these designated centers are authorized to administer the therapies under the CGT Access Model.

Provider Responsibilities

Providers participating in the CGT Access Model must:

- Follow the Medicaid Provider Manual requirements for FFS drug carve-outs.
- Participate in the CIBMTR registry and comply with all CMS-required data collection and outcomes studies.
- Coordinate directly with MDHHS for authorization and reimbursement.
- Notify ABHMI as early as possible when a member is being evaluated for Casgevy® or Lyfgenia® to support care coordination.

MDHHS Provider Support

- Email: **ProviderSupport@michigan.gov**
- Phone: 1-800-292-2550

Aetna Better Health® of Michigan

ABHMI Care Coordination Responsibilities

Although the gene therapy product is covered through Medicaid FFS, ABHMI remains responsible for coordinating the member's overall care.

ABHMI will:

- Coordinate all medical and ancillary services related to treatment.
- Ensure access to the same providers for at least one year post-infusion, when clinically appropriate.
- Honor existing prior authorizations during transitions of care, including coverage of out-of-network services when needed.
- Provide Care Management support throughout evaluation, treatment, and long-term follow-up.
- Assist members with transportation, lodging, scheduling, medications, psychosocial needs, and ongoing monitoring.

Action Required:
Providers should review CGT Access Model requirements and notify ABHMI early when evaluating members for Casgevy® or Lyfgenia® to ensure timely coordination of services.

For additional support or questions please contact us at

Care Management: Email: **aetnabetterhealthofmi-cmmailbox@aetna.com**

- Website: https://www.aetnabetterhealth.com/michigan/providers/index.html
- Phone: 1-866-316-3784